Table II.
Hemostatic parameters in Mirasol-treated and control platelets
| Parameter/day | Median (IQR) | p-value | |
|---|---|---|---|
| Mirasol | Control | ||
| LTA ADP (%), 1 | 30 (21–57) | 41.5 (9–61) | 0.96 |
| LTA ADP (%), 3 | 17.5 (7–28) | 3.5 (1–9) | 0.017 |
| LTA ADP (%), 5 | 6.5 (0–16) | 4 (2–11) | 0.96 |
| LTA ADP (%), 7 | 1.5 (0–8) | 6 (2–15) | 0.24 |
| p-value | <0.001 | 0.002 | |
| Annexin-V, 1 | 2.6 (1.6–4) | 2.6 (1.9–5) | 0.96 |
| Annexin-V, 3 | 6.1 (4–8.3) | 4.6 (3.5–5.8) | 0.27 |
| Annexin-V, 5 | 7.8 (4.3–12.4) | 6.4 (3.6–9.3) | 0.48 |
| Annexin-V, 7 | 37.2 (29.1–48.6) | 6.2 (4.3–7) | <0.001 |
| p-value | <0.001 | 0.13 | |
| CT EXTEM (sec), 1 | 82.5 (69–95) | 79.5 (71–88) | 0.73 |
| CT EXTEM (sec), 3 | 76.5 (65–89) | 67.5 (61–79) | 0.22 |
| CT EXTEM (sec), 5 | 70.5 (69–73) | 69 (66–74) | 0.76 |
| CT EXTEM (sec), 7 | 72.5 (65–81) | 70.5 (68–73) | 0.62 |
| A10 EXTEM (mm), 1 | 56.5 (49–57) | 59 (54–63) | 0.30 |
| A10 EXTEM (mm), 3 | 33.5 (29–43) | 54 (44–58) | 0.012 |
| A10 EXTEM (mm), 5 | 23 (19–27) | 51.5 (42–55) | 0.001 |
| A10 EXTEM (mm), 7 | 22 (19–29) | 49.5 (45–56) | 0.001 |
| p-value | <0.001 | 0.17 | |
| A10 FIBTEM (mm), 3 | 19 (17–22) | 20.5 (17–23) | 0.44 |
| A10 FIBTEM (mm), 5 | 20 (17–21) | 21 (20–22) | 0.10 |
| A10 FIBTEM (mm), 7 | 20 (17–24) | 20.5 (18–24.5) | 0.68 |
| p-value | 0.86 | 0.71 | |
| CFT EXTEM (sec), 1 | 55.5 (46–82) | 48.5 (40–65) | 0.40 |
| CFT EXTEM (sec), 3 | 66 (58–94) | 54 (46–86) | 0.09 |
| CFT EXTEM (sec), 5 | 109 (86–130) | 61 (51–91) | 0.005 |
| CFT EXTEM (sec), 7 | 147 (88–543) | 54 (51–73) | <0.001 |
| p-value | <0.001 | 0.46 | |
| MCF EXTEM (mm), 1 | 60 (52–61) | 61 (57–67) | 0.40 |
| MCF EXTEM (mm), 3 | 37.5 (30–43) | 54.5 (45–59) | 0.009 |
| MCF EXTEM (mm), 5 | 24.5 (19–32) | 51.5 (43–56) | <0.001 |
| MCF EXTEM (mm), 7 | 24 (19–30) | 49.5 (45–57) | 0.001 |
| p-value | <0.001 | 0.058 | |
| MCF FIBTEM (mm), 3 | 21 (19–24) | 22.5 (20–25) | 0.36 |
| MCF FIBTEM (mm), 5 | 22 (19–25) | 23 (23–25) | 0.38 |
| MCF FIBTEM (mm), 7 | 22 (20–27) | 23 (21–26.5) | 0.68 |
| MCE EXTEM, 3 | 60.5 (43–75) | 121 (81–143) | 0.009 |
| MCE EXTEM, 5 | 30.5 (24–41) | 106 (74–125) | <0.001 |
| MCE EXTEM, 7 | 31.5 (24–43) | 97 (81–130) | 0.001 |
| p-value | <0.001 | 0.059 | |
| MA TEG (mm), 1 | 75.3 (73.2–76.7) | 77.5 (76.6–80.3) | 0.10 |
| MA TEG (mm), 3 | 72.4 (70.0–75.1) | 76.8 (75.5–78.1) | 0.010 |
| MA TEG (mm), 5 | 69.4 (65.9–70.8) | 76.7 (75.5–78.9) | 0.001 |
| MA TEG (mm), 7 | 60.3 (52.0–63.2) | 76.5 (75.0–81.0) | <0.001 |
| p-value | <0.001 | 0.90 | |
| R TEG (min), 1 | 0.7 (0.6–0.8) | 0.7 (0.6–0.7) | 0.72 |
| R TEG (min), 3 | 0.6 (0.5–0.7) | 0.7 (0.5–0.7) | 0.71 |
| R TEG (min), 5 | 0.5 (0.5–0.8) | 0.6 (0.6–0.7) | 0.34 |
| R TEG (min), 7 | 0.6 (0.5–0.7) | 0.7 (0.6–0.8) | 0.35 |
| p-value | 0.68 | 0.73 | |
| K TEG (min), 1 | 0.8 (0.8–0.8) | 0.8 (0.8–0.8) | 0.95 |
| K TEG (min), 3 | 0.8 (0.8–0.8) | 0.8 (0.8–0.8) | 0.31 |
| K TEG (min), 5 | 0.8 (0.8–0.8) | 0.8 (0.8–0.8) | 0.14 |
| K TEG (min), 7 | 0.9 (0.8–1.2) | 0.8 (0.8–0.8) | 0.018 |
| p-value | 0.006 | 0.39 | |
p-values in bold stand for statistically significant results (p<0.05). IQR: interquartile range; LTA: light transmission aggregometry; EPI: epinephrine; ADP: adenosine diphosphate; CT: clotting time; CFT: clot formation time; A10: amplitude 10 min after CT; MCF: maximum clot firmness; LI60: lysis index at 60 minutes; MCE: maximum clot elasticity; TEG: thromboelastography; MA: maximum amplitude; LY60: lysis value at 60 minutes.